193 related articles for article (PubMed ID: 37967215)
1. NMDAR antagonists suppress tumor progression by regulating tumor-associated macrophages.
Yuan D; Hu J; Ju X; Putz EM; Zheng S; Koda S; Sun G; Deng X; Xu Z; Nie W; Zhao Y; Li X; Dougall WC; Shao S; Chen Y; Tang R; Zheng K; Yan J
Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2302126120. PubMed ID: 37967215
[TBL] [Abstract][Full Text] [Related]
2. Blocking MARCO
Ding L; Qian J; Yu X; Wu Q; Mao J; Liu X; Wang Y; Guo D; Su R; Xie H; Yin S; Zhou L; Zheng S
Cancer Lett; 2024 Feb; 582():216568. PubMed ID: 38065400
[TBL] [Abstract][Full Text] [Related]
3. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
4. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
La Fleur L; Botling J; He F; Pelicano C; Zhou C; He C; Palano G; Mezheyeuski A; Micke P; Ravetch JV; Karlsson MCI; Sarhan D
Cancer Res; 2021 Feb; 81(4):956-967. PubMed ID: 33293426
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumor-associated macrophages for cancer immunotherapy.
Cao X; Lai SWT; Chen S; Wang S; Feng M
Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930
[TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
8. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
9. Targeting tumor associated macrophages in hepatocellular carcinoma.
Xu W; Cheng Y; Guo Y; Yao W; Qian H
Biochem Pharmacol; 2022 May; 199():114990. PubMed ID: 35288152
[TBL] [Abstract][Full Text] [Related]
10. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.
Eisinger S; Sarhan D; Boura VF; Ibarlucea-Benitez I; Tyystjärvi S; Oliynyk G; Arsenian-Henriksson M; Lane D; Wikström SL; Kiessling R; Virgilio T; Gonzalez SF; Kaczynska D; Kanatani S; Daskalaki E; Wheelock CE; Sedimbi S; Chambers BJ; Ravetch JV; Karlsson MCI
Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32005-32016. PubMed ID: 33229588
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function.
Petty AJ; Dai R; Lapalombella R; Baiocchi RA; Benson DM; Li Z; Huang X; Yang Y
JCI Insight; 2021 Mar; 6(6):. PubMed ID: 33749663
[TBL] [Abstract][Full Text] [Related]
12. TFEB is a master regulator of tumor-associated macrophages in breast cancer.
Li Y; Hodge J; Liu Q; Wang J; Wang Y; Evans TD; Altomare D; Yao Y; Murphy EA; Razani B; Fan D
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487570
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated macrophages in liver cancer: From mechanisms to therapy.
Cheng K; Cai N; Zhu J; Yang X; Liang H; Zhang W
Cancer Commun (Lond); 2022 Nov; 42(11):1112-1140. PubMed ID: 36069342
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma.
Sung PS
Clin Mol Hepatol; 2022 Jul; 28(3):333-350. PubMed ID: 34665953
[TBL] [Abstract][Full Text] [Related]
15. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy.
Rodriguez-Garcia A; Lynn RC; Poussin M; Eiva MA; Shaw LC; O'Connor RS; Minutolo NG; Casado-Medrano V; Lopez G; Matsuyama T; Powell DJ
Nat Commun; 2021 Feb; 12(1):877. PubMed ID: 33563975
[TBL] [Abstract][Full Text] [Related]
16. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.
Han Z; Wu X; Qin H; Yuan YC; Schmolze D; Su C; Zain J; Moyal L; Hodak E; Sanchez JF; Lee PP; Feng M; Rosen ST; Querfeld C
JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37427589
[TBL] [Abstract][Full Text] [Related]
17. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of HMGB1 inhibits the crosstalk between oral squamous cell carcinoma cells and tumor-associated macrophages.
Wen J; Yin P; Su Y; Gao F; Wu Y; Zhang W; Chi P; Chen J; Zhang X
Int Immunopharmacol; 2023 Jun; 119():110259. PubMed ID: 37141670
[TBL] [Abstract][Full Text] [Related]
20. The role of tumor-associated macrophage in breast cancer biology.
Choi J; Gyamfi J; Jang H; Koo JS
Histol Histopathol; 2018 Feb; 33(2):133-145. PubMed ID: 28681373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
